secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2021-08-20T23:59:59+00:00
Accession:  0001104659-21-108145
Event type: leadership
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx Pharmaceuticals appoints Daniel Geffken as Principal Accounting Officer
-----------------------------------------------------------------------------

- Daniel Geffken, Interim CFO since April 1, 2021, added role of Principal Accounting Officer on August 17, 2021.
- Geffken provides services through Danforth Advisors, LLC.
- No departure or change in CFO role; Geffken remains Principal Financial Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465921108145/0001104659-21-108145-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465921108145/tm2125622d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-108145

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer